Antiretroviral-Sparing Concept With HIV-specific T Cell Precursors With High Proliferative Capacity (PHPC)
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
PHPC-02 is a phase II, randomized, placebo-controlled trial designed to investigate whether
therapeutic immunization during highly active antiretroviral therapy (HAART) induces
elevations of HIV-specific T cell precursors with high proliferative capacity (PHPC) in
HIV-1-infected individuals, and whether the quantity of PHPC correlates with the viral load
set point following analytical treatment interruption (ATI). Subjects will be randomized to
receive either DermaVir Patch (8 subjects per cohort) or DermaVir Patch Placebo (8 subjects
per cohort) every four weeks for three applications while receiving maximally suppressive
HAART. HAART will be discontinued at Week 9 for an ATI period of 20 weeks.